BioCardia Inc BCDA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if BCDA is a good fit for your portfolio.
News
-
Patient Enrollment Commenced in Pivotal Phase 3 Trial of CardiAMP Cell Therapy for the Treatment of Ischemic Heart Failure
-
BioCardia Announces United States Patent Issuance on Morph DNA Multi-Directional Steerable Catheter Transseptal Application
-
CellProthera and BioCardia Collaborate on Successful Phase II Trial of ProtheraCytes™ for the Treatment of Acute Myocardial Infarction
-
BioCardia Announces United States Patent Issuance on Intramyocardial Delivery of Cell Aggregates to the Heart Including Minimally Invasive Radial Artery Approach
-
BioCardia Announces Reverse Stock Split
-
BioCardia Reports First Quarter 2024 Business Highlights and Financial Results
-
BioCardia to Host Q1 2024 Financial Results and Corporate Update Conference Call on May 14, 2024
-
BioCardia’s CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes
Trading Information
- Previous Close Price
- $2.95
- Day Range
- $2.90–3.15
- 52-Week Range
- $2.62–23.25
- Bid/Ask
- $2.99 / $3.12
- Market Cap
- $5.46 Mil
- Volume/Avg
- 19,967 / 156,044
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 9.55
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP® autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an “off the shelf” cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO™), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 20
- Website
- https://www.biocardia.com
Comparables
Valuation
Metric
|
BCDA
|
CBAY
|
OBIO
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | 12.65 | 4.71 |
Price/Sales | 9.55 | 111.01 | 119.81 |
Price/Cash Flow | — | — | — |
Price/Earnings
BCDA
CBAY
OBIO
Financial Strength
Metric
|
BCDA
|
CBAY
|
OBIO
|
---|---|---|---|
Quick Ratio | 0.25 | 10.70 | 7.21 |
Current Ratio | 0.31 | 10.96 | 7.34 |
Interest Coverage | — | −5.27 | — |
Quick Ratio
BCDA
CBAY
OBIO
Profitability
Metric
|
BCDA
|
CBAY
|
OBIO
|
---|---|---|---|
Return on Assets (Normalized) | −197.17% | −30.06% | −37.47% |
Return on Equity (Normalized) | — | −51.97% | −52.90% |
Return on Invested Capital (Normalized) | −757.16% | −30.87% | −52.84% |
Return on Assets
BCDA
CBAY
OBIO
Biotechnology Industry Comparables
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|---|
Novo Nordisk A/S ADR
NVO
| Jdhsrbkny | Lbyn | $565.6 Bil | |||
Vertex Pharmaceuticals Inc
VRTX
| Pfxmgyj | Fcxljj | $127.8 Bil | |||
Regeneron Pharmaceuticals Inc
REGN
| Mmwjftgs | Ltddgp | $118.7 Bil | |||
Moderna Inc
MRNA
| Zhxtgvr | Gkn | $46.8 Bil | |||
Alnylam Pharmaceuticals Inc
ALNY
| Bmrgmlrh | Whjhkd | $29.7 Bil | |||
argenx SE ADR
ARGX
| Gqpxtmp | Rkhr | $29.3 Bil | |||
BioNTech SE ADR
BNTX
| Qykwdgwr | Dfqy | $20.7 Bil | |||
Biomarin Pharmaceutical Inc
BMRN
| Yltnyzjh | Czfwzz | $16.1 Bil | |||
United Therapeutics Corp
UTHR
| Smptvqxbl | Qmrp | $15.0 Bil | |||
Incyte Corp
INCY
| Lpkykvwl | Nqfgkjn | $13.5 Bil |